BIOLYTEÂ Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • BIOLYTEÂ's estimated annual revenue is currently $6.5M per year.(i)
  • BIOLYTEÂ's estimated revenue per employee is $216,000

Employee Data

  • BIOLYTEÂ has 30 Employees.(i)
  • BIOLYTEÂ grew their employee count by -30% last year.

BIOLYTEÂ's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP MarketingReveal Email/Phone
3
VP Business Development-HealthcareReveal Email/Phone
4
Director Talent ManagementReveal Email/Phone
5
Director ProcurementReveal Email/Phone
6
Regional Sales ManagerReveal Email/Phone
7
Experiential Marketing ManagerReveal Email/Phone
8
National Pharmacy Account ManagerReveal Email/Phone
9
Logistics ManagerReveal Email/Phone
10
Regional Sales Manager- FL/AL/MS/TNReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17M703%N/AN/A
#2
$36.5M13515%N/AN/A
#3
$0.1M10%N/AN/A
#4
$17.3M716%N/AN/A
#5
$25.7M9517%N/AN/A
#6
$13.4M550%N/AN/A
#7
$23M850%N/AN/A
#8
$49.3M1667%N/AN/A
#9
$42.8M1447%N/AN/A
#10
$6.7M313%N/AN/A
Add Company

What Is BIOLYTEÂ?

BIOLYTE®, the IV in a bottle® is the first liquid supplement that offers the same benefits of IV rehydration therapy, but in a drinkable form. Our founder, Dr. Rollins, wanted to create a product that would bring the IV bag home to his wife when she was going through breast cancer. He used his experience in the hospital tailoring IV bags to his patients needs, to create BIOLYTE®, the IV in a bottle. Just one bottle of BIOLYTE® has the same amount of electrolytes as an IV bag plus natural ingredients that boost energy, ease stomach illness, and reduce muscle cramps. BIOLYTE® is family owned and on a mission to help people feel better.

keywords:N/A

N/A

Total Funding

30

Number of Employees

$6.5M

Revenue (est)

-30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M30-6%N/A
#2
$4.9M30-9%N/A
#3
$7.8M30-27%N/A
#4
$6.5M3011%N/A
#5
$3.6M307%N/A